You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErythromycin
Accession NumberDB00199  (APRD00953)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionErythromycin is a macrolide antibiotic produced by Streptomyces erythreus. It inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits; binding inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Structure
Thumb
Synonyms
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
3''-O-demethylerythromycin
Abomacetin
Eritromicina
Erythromycin
Erythromycin A
Erythromycin C
Erythromycine
Erythromycinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-erythromycin Tab 250mg USPtablet (enteric-coated)250 mgoralAltimed Pharma Inc.1985-12-311999-09-17Canada
Diomycin-ont 5mg/gmointment5 mgophthalmicDioptic Pharmaceuticals Inc1997-09-11Not applicableCanada
E.E.sgranule, for suspension200 mg/5mLoralA S Medication Solutions Llc2011-04-18Not applicableUs
E.E.sgranule, for suspension200 mg/5mLoralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
E.E.sgranule, for suspension200 mg/5mLoralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ees 600 Tablets 600mgtablet600 mgoralAmdipharm Limited1983-12-31Not applicableCanada
Ees-200powder for suspension40 mgoralAmdipharm Limited1962-12-31Not applicableCanada
Ees-200 Chewable Tbs (eryped)tablet200 mgoralAbbott Laboratories, Limited1964-12-311997-08-18Canada
Ees-400powder for suspension400 mgoralAmdipharm Limited1978-12-31Not applicableCanada
Emycin Ect 250mgtablet (enteric-coated)250 mgoralThe Upjohn Company Of Canada1969-12-311996-09-10Canada
Ery-pedsuspension200 mg/5mLoralArbor Pharmaceuticals, Inc.2011-07-05Not applicableUs
Ery-pedsuspension400 mg/5mLoralArbor Pharmaceuticals, Inc.2012-06-14Not applicableUs
Erybidtablet500 mgoralAmdipharm Limited1990-12-31Not applicableCanada
Eryc Delayed-release Capsulescapsule (enteric-coated)333 mgoralPfizer Canada Inc1990-12-31Not applicableCanada
Eryc Delayed-release Capsulescapsule (enteric-coated)250 mgoralPfizer Canada Inc1983-12-31Not applicableCanada
Erygelgel20 mg/gtopicalPrestium Pharma, Inc.2016-01-27Not applicableUs
Erymycin Ophthalmic Ointment 5mg/gointment5 mgophthalmicMm Therapeutics Inc1998-06-042011-01-05Canada
Erythro-500 Tab 500mg USPtablet500 mgoralPro Doc Limitee1987-12-312009-07-23Canada
Erythro-basetablet250 mgoralAa Pharma Inc1986-12-31Not applicableCanada
Erythro-base Tab 250mg USPtablet250 mgoralPro Doc Limitee1987-12-312009-07-23Canada
Erythro-ECcapsule (enteric-coated)250 mgoralAa Pharma Inc1989-12-312014-11-07Canada
Erythro-ECcapsule (enteric-coated)333 mgoralAa Pharma Inc1991-12-312014-11-07Canada
Erythro-EStablet600 mgoralAa Pharma Inc1986-12-31Not applicableCanada
Erythro-ES Tab 600mg USPtablet600 mgoralPro Doc Limitee1987-12-312009-07-23Canada
Erythro-Stablet250 mgoralAa Pharma Inc1981-12-31Not applicableCanada
Erythro-Stablet500 mgoralAa Pharma Inc1986-12-31Not applicableCanada
Erythrocin Filmtab 250mgtablet250 mgoralAbbott Laboratories, Limited1955-12-311999-08-09Canada
Erythrocin Filmtab 500mgtablet500 mgoralAbbott Laboratories, Limited1973-12-311999-08-09Canada
Erythrocin I.V.powder for solution1 gintravenousAmdipharm Limited1988-12-31Not applicableCanada
Erythrocin I.V.powder for solution500 mgintravenousAmdipharm Limited1988-12-31Not applicableCanada
Erythrocin IVpowder for solution1 gintravenousAbbott Laboratories, Limited1954-12-311996-11-04Canada
Erythrocin IVpowder for solution500 mgintravenousAbbott Laboratories, Limited1966-12-311996-11-04Canada
Erythrocin Lactobionateinjection, powder, lyophilized, for solution500 mg/10mLintravenousHospira, Inc.1986-09-24Not applicableUs
Erythrocin Liq 250liquid50 mgoralAbbott Laboratories, Limited1973-12-312006-06-12Canada
Erythrocin Liquid 125liquid25 mgoralAbbott Laboratories, Limited1970-12-312006-06-12Canada
Erythromid Tab 250mgtablet250 mgoralAbbott Laboratories, Limited1972-12-312008-06-06Canada
Erythromycingel20 mg/gtopicalRenaissance Pharma, Inc.2015-07-01Not applicableUs
Erythromycincapsule, delayed release pellets250 mg/1oralMidlothian Laboratories2013-07-29Not applicableUs
Erythromycin Capsules USP 250mgcapsule250 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Erythromycin Ophthalmic Ointment U.S.P.ointment5 mgophthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Erythromycin Stearate Tablets USP 250mgtablet250 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Erythromycine 250 Tabtablet250 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Ilosone 250mg Pulvule 375capsule250 mgoralEli Lilly Canada Inc1956-12-312000-08-03Canada
Ilosone Liquid 125mg/5mlsuspension125 mgoralEli Lilly Canada Inc1968-12-311999-08-11Canada
Ilosone Liquid 250mg/5mlsuspension250 mgoralEli Lilly Canada Inc1972-12-312000-08-03Canada
Ilotycin Cryst Op Ont 0.5% 52ointment.5 %ophthalmicEli Lilly Canada Inc1954-12-312002-07-26Canada
Ilotycin Gluceptate IV Ampoule 646 1gmpowder for solution1 gintravenousEli Lilly Canada Inc1957-12-311999-09-13Canada
Novo-rythro Encap 250mgcapsule (enteric-coated)250 mgoralNovopharm Limited1990-12-312005-08-10Canada
Novo-rythro Estolate Cap 250mgcapsule250 mgoralNovopharm Limited1970-12-312005-08-10Canada
Novo-rythro Estolate Suspensionsuspension125 mgoralTeva Canada Limited1970-12-31Not applicableCanada
Novo-rythro Estolate Suspensionsuspension250 mgoralTeva Canada Limited1973-12-31Not applicableCanada
Novo-rythro Ethylsuccinate Pwr 400mg/5mlpowder400 mgoralNovopharm Limited1985-12-312015-10-26Canada
Novo-rythro Ethylsuccinate Pwspowder for solution200 mgoralNovopharm Limited1984-12-312015-10-26Canada
Novo-rythro Ethylsuccinate Pwspowder for solution100 mgoralNovopharm Limited1984-12-312005-08-10Canada
Novo-rythro Stearate Tab 250mgtablet250 mgoralNovopharm Limited1977-12-312005-08-10Canada
Nu-erythromycin-S 250mg Tabletstablet250 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Odan-erythromycinointment5 mgophthalmicOdan Laboratories Ltd1992-12-31Not applicableCanada
Onguent Ophtalmique D'erythromycine USPointment5 mgophthalmicLaboratoires Sterigen Inc2010-02-12Not applicableCanada
Pcetablet333 mg/1oralArbor Pharmaceuticals, Inc.2011-10-05Not applicableUs
Pcetablet333 mgoralAmdipharm Limited1988-12-31Not applicableCanada
Pcetablet500 mg/1oralArbor Pharmaceuticals, Inc.2011-10-05Not applicableUs
Pdp-erythromycinointment5 mgophthalmicPendopharm Division Of De Pharmascience Inc1991-12-31Not applicableCanada
Sterile Erythromycin Lactobionate Pws 1000mgpowder for solution1 gintravenousNovopharm Limited1992-12-312015-10-26Canada
Sterile Erythromycin Lactobionate Pws 500mgpowder for solution500 mgintravenousNovopharm Limited1992-12-312015-10-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
E.E.s 400tablet400 mg/1oralArbor Pharmaceuticals, Inc.2011-05-03Not applicableUs
E.E.S.tablet, film coated400 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-16Not applicableUs
E.E.S.tablet, film coated400 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-16Not applicableUs
Erysolution.8 mL/100mLtopicalPerrigo New York Inc2008-07-07Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralPd Rx Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release250 mg/1oralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralA S Medication Solutions Llc2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralCarilion Materials Management2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralKAISER FOUNDATION HOSPITALS2009-08-28Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralPd Rx Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralA S Medication Solutions Llc2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralSTAT Rx USA LLC2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralPhysicians Total Care, Inc.1999-09-28Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralPhysicians Total Care, Inc.2004-06-30Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralArbor Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet, delayed release250 mg/1oralA S Medication Solutions Llc2011-04-18Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralSTAT Rx USA LLC2011-04-18Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralREMEDYREPACK INC.2011-08-24Not applicableUs
Ery-tabtablet, delayed release333 mg/1oralRebel Distributors Corp1972-07-11Not applicableUs
Ery-tabtablet, delayed release250 mg/1oralCarilion Materials Management2011-04-18Not applicableUs
Ery-tabtablet, delayed release500 mg/1oralPd Rx Pharmaceuticals, Inc.2011-04-18Not applicableUs
Ery-tabtablet333 mg/1oralREMEDYREPACK INC.2011-08-19Not applicableUs
Erygelgel20 mg/gtopicalPrestium Pharma, Inc.2014-01-27Not applicableUs
Erythrocin Lactobionateinjection, powder, lyophilized, for solution500 mg/100mLintravenousHospira, Inc.1986-10-31Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralREMEDYREPACK INC.2013-03-05Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralA S Medication Solutions Llc2011-08-01Not applicableUs
Erythrocin Stearatetablet500 mg/1oralREMEDYREPACK INC.2012-08-27Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralArbor Pharmaceuticals, Inc.2011-08-01Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralBlenheim Pharmacal, Inc.2010-03-09Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralA S Medication Solutions Llc2011-08-01Not applicableUs
Erythrocin Stearatetablet, film coated500 mg/1oralbryant ranch prepack1964-06-24Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralKAISER FOUNDATION HOSPITALS2012-01-06Not applicableUs
Erythrocin Stearatetablet, film coated250 mg/1oralPd Rx Pharmaceuticals, Inc.2011-08-01Not applicableUs
Erythrocin Stearatetablet, film coated500 mg/1oralBlenheim Pharmacal, Inc.2010-09-14Not applicableUs
Erythromycinointment5 mg/gophthalmicH.J. Harkins Company, Inc.1994-07-29Not applicableUs
Erythromycinointment5 g/1ophthalmicDIRECT RX2014-01-01Not applicableUs
Erythromycinointment5 mg/gophthalmicBausch & Lomb Incorporated1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicPreferred Pharmaceuticals, Inc.2014-07-03Not applicableUs
Erythromycinsolution20 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1997-09-30Not applicableUs
Erythromycintablet, film coated250 mg/1oralSTAT Rx USA LLC1972-07-11Not applicableUs
Erythromycinointment5 mg/gophthalmicMwi2015-03-23Not applicableUs
Erythromycintablet, film coated500 mg/1oralArbor Pharmaceuticals, Inc.2011-09-06Not applicableUs
Erythromycinointment5 mg/gophthalmicFera Pharmaceuticals2010-01-18Not applicableUs
Erythromycinointment5 mg/gophthalmicCardinal Health1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicPhysicians Total Care, Inc.1994-09-01Not applicableUs
Erythromycinointment5 mg/gophthalmicCentral Texas Community Health Centers1994-07-29Not applicableUs
Erythromycinsolution20 mg/mLtopicalPerrigo New York Inc2011-12-19Not applicableUs
Erythromycingel20 mg/gtopicalAidarex Pharmaceuticals LLC2008-06-12Not applicableUs
Erythromycinointment5 mg/gophthalmicProficient Rx LP1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicPaddock Laboratories, LLC2014-05-08Not applicableUs
Erythromycingel20 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1997-09-30Not applicableUs
Erythromycinointment5 mg/gophthalmicAkorn, Inc.1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicPreferred Pharmaceuticals, Inc.2013-08-05Not applicableUs
Erythromycincapsule, delayed release250 mg/1oralStat Rx USA1986-12-22Not applicableUs
Erythromycincapsule, delayed release250 mg/1oralA S Medication Solutions Llc2012-01-10Not applicableUs
Erythromycinointment5 mg/gophthalmicHenry Schein Inc.2015-05-13Not applicableUs
Erythromycinsolution20 mg/mLtopicalMorton Grove Pharmaceuticals, Inc.1987-10-23Not applicableUs
Erythromycinointment5 mg/gophthalmicREMEDYREPACK INC.2013-12-31Not applicableUs
Erythromycinointment5 mg/gophthalmicAkorn, Inc.2013-03-11Not applicableUs
Erythromycintablet, film coated250 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Erythromycinointment5 mg/gophthalmicCardinal Health1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicPreferred Pharmaceuticals, Inc.1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicREMEDYREPACK INC.2013-05-06Not applicableUs
Erythromycinsolution20 mg/1topicalPhysicians Total Care, Inc.1996-03-29Not applicableUs
Erythromycinsolution20 mg/mLtopicalVersa Pharm Incorporated2010-08-01Not applicableUs
Erythromycintablet, film coated250 mg/1oralArbor Pharmaceuticals, Inc.2011-09-06Not applicableUs
Erythromycingel20 mg/gtopicalPerrigo New York Inc2008-06-12Not applicableUs
Erythromycinointment5 mg/gophthalmicA S Medication Solutions Llc1996-07-18Not applicableUs
Erythromycinointment5 mg/gophthalmicDispensing Solutions, Inc.1996-07-18Not applicableUs
Erythromycincapsule, delayed release250 mg/1oralKAISER FOUNDATION HOSPITALS2012-04-26Not applicableUs
Erythromycinointment5 mg/gophthalmicRebel Distributors Corp1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-01-18Not applicableUs
Erythromycinointment5 mg/gophthalmicProficient Rx LP1994-07-29Not applicableUs
Erythromycinointment5 mg/gophthalmicPreferred Pharmaceuticals, Inc.2015-04-02Not applicableUs
Erythromycinointment5 mg/gophthalmicStat Rx USA1994-07-29Not applicableUs
Erythromycincapsule, delayed release250 mg/1oralArbor Pharmaceuticals, Inc.2012-01-10Not applicableUs
Erythromycin Basetablet, film coated250 mg/1oralCarilion Materials Management2011-09-06Not applicableUs
Erythromycin Basetablet, film coated250 mg/1oralA S Medication Solutions Llc2011-09-06Not applicableUs
Erythromycin Basetablet, film coated500 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-09-06Not applicableUs
Erythromycin Basetablet, film coated500 mg/1oralA S Medication Solutions Llc2011-09-06Not applicableUs
Erythromycin Basetablet, film coated500 mg/1oralPd Rx Pharmaceuticals, Inc.2011-09-06Not applicableUs
Erythromycin Base Basetablet, film coated250 mg/1oralPd Rx Pharmaceuticals, Inc.2011-09-06Not applicableUs
Erythromycin Base Basetablet, film coated500 mg/1oralREMEDYREPACK INC.2013-03-04Not applicableUs
Erythromycin Base Basetablet, film coated250 mg/1oralREMEDYREPACK INC.2013-03-14Not applicableUs
Erythromycin Base Filmtabtablet, film coated250 mg/1oralPhysicians Total Care, Inc.1995-07-21Not applicableUs
Erythromycin Base Filmtabtablet, film coated250 mg/1oralRebel Distributors Corp1972-07-11Not applicableUs
Erythromycin Base Filmtabtablet, film coated500 mg/1oralPhysicians Total Care, Inc.1996-12-09Not applicableUs
Erythromycin Base Filmtabtablet, film coated500 mg/1oralCardinal Health2011-09-08Not applicableUs
Erythromycin Base Filmtabtablet, film coated500 mg/1oralRebel Distributors Corp1972-07-11Not applicableUs
Erythromycin Base Filmtabtablet, film coated500 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-12Not applicableUs
Erythromycin Ethylsuccinatetablet400 mg/1oralA S Medication Solutions Llc2011-10-03Not applicableUs
Erythromycin Ethylsuccinatetablet400 mg/1oralArbor Pharmaceuticals, Inc.2011-10-03Not applicableUs
Erythromycin Ethylsuccinatetablet400 mg/1oralPhysicians Total Care, Inc.1996-02-27Not applicableUs
Ilotycinointment5 mg/gophthalmicPaddock Laboratories, LLC2014-10-08Not applicableUs
Ilotycinointment.5 mg/gophthalmicFera Pharmaceuticals, LLC2010-10-12Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ErycHospira
IlosoneCipa
StaticinWestwood
T-statWestwood
Brand mixtures
NameLabellerIngredients
BenzamycinDermik Laboratories
ErysolGlaxosmithkline Inc
Erythromycin and Benzoyl PeroxideLyne Laboratories, Inc.
Erythromycin Ethylsuccinate and Sulfisoxazole AcetylRebel Distributors Corp
Erythromycin-benzoyl PeroxidePerrigo New York Inc
PediazoleAmdipharm Limited
Sans-acne SolutionGalderma Canada Inc
Stievamycin ForteGlaxosmithkline Inc
Stievamycin MildGlaxosmithkline Inc
Stievamycin RegularGlaxosmithkline Inc
T-stat LotWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
T-stat Pad-lotWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Salts
Name/CASStructureProperties
Erythromycin estolate
ThumbNot applicableDBSALT001358
Erythromycin ethylsuccinate
ThumbNot applicableDBSALT001220
Erythromycin gluceptate
ThumbNot applicableDBSALT001340
Erythromycin lactobionate
ThumbNot applicableDBSALT001219
Erythromycin phosphate
ThumbNot applicableDBSALT001624
Erythromycin stearate
ThumbNot applicableDBSALT001221
Erythromycin thiocyanate
ThumbNot applicableDBSALT001625
Categories
UNII63937KV33D
CAS number114-07-8
WeightAverage: 733.9268
Monoisotopic: 733.461241235
Chemical FormulaC37H67NO13
InChI KeyInChIKey=ULGZDMOVFRHVEP-RWJQBGPGSA-N
InChI
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
SMILES
CC[[email protected]]1OC(=O)[[email protected]](C)[C@@H](O[[email protected]]2C[C@@](C)(OC)[C@@H](O)[[email protected]](C)O2)[[email protected]](C)[C@@H](O[C@@H]2O[[email protected]](C)C[C@@H]([[email protected]]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[[email protected]](C)[C@@H](O)[C@]1(C)O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolides and analogues
Sub ClassNot Available
Direct ParentMacrolides and analogues
Alternative Parents
Substituents
  • Macrolide
  • Amino sugar
  • Desosamine
  • Amino saccharide
  • Oxane
  • Monosaccharide
  • Saccharide
  • Tertiary alcohol
  • Cyclic ketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Polyol
  • Lactone
  • Ketone
  • Carboxylic acid ester
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to Corynebacterium diphtheriae, in the treatment of infections due to Corynebacterium minutissimum, intestinal amebiasis caused by Entamoeba histolytica, acute pelvic inflammatory disease caused by Neisseria gonorrhoeae, skin and soft tissue infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus, primary syphilis caused by Treponema pallidum, infections caused by Chlamydia trachomatis, nongonococcal urethritis caused by Ureaplasma urealyticum, and Legionnaires' disease caused by Legionella pneumophila.
PharmacodynamicsErythromycin is produced by a strain of Streptomyces erythraeus and belongs to the macrolide group of antibiotics. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin is excreted in breast milk. The drug crosses the placental barrier with fetal serum drug levels reaching 5 - 20% of maternal serum concentrations. Erythromycin is not removed by peritoneal dialysis or hemodialysis.
Mechanism of actionErythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the “P” or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the “A” or acceptor site to the “P” or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.
Related Articles
AbsorptionOrally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Topical application of the ophthalmic ointment to the eye may result in absorption into the cornea and aqueous humor.
Volume of distributionNot Available
Protein bindingErythromycin is largely bound to plasma proteins, ranging from 75 - 95% binding depending on the form.
Metabolism

Hepatic. Extensively metabolized - after oral administration, less than 5% of the administered dose can be recovered in the active form in the urine. Erythromycin is partially metabolized by CYP3A4 resulting in numerous drug interactions.

SubstrateEnzymesProduct
Erythromycin
norerythromycinDetails
Route of eliminationNot Available
Half life0.8 - 3 hours
ClearanceNot Available
ToxicitySymptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Streptococcus pyogenes
  • Haemophilus influenzae
  • Staphylococcus aureus
Pathways
PathwayCategorySMPDB ID
Erythromycin Action PathwayDrug actionSMP00250
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5114
Blood Brain Barrier-0.9889
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8098
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.5963
Renal organic cation transporterNon-inhibitor0.9222
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9225
CYP450 3A4 substrateSubstrate0.6528
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9074
CYP450 3A4 inhibitorNon-inhibitor0.5744
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9391
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9335
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2296 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9902
hERG inhibition (predictor II)Non-inhibitor0.8956
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Parke davis div warner lambert co
  • Warner chilcott inc
  • Abbott laboratories pharmaceutical products div
  • Barr laboratories inc
  • Stiefel laboratories inc
  • Altana inc
  • Merz pharmaceuticals llc
  • Perrigo co
  • Syosset laboratories inc
  • Akorn inc
  • Bausch and lomb pharmaceuticals inc
  • E fougera div altana inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Dista products co div eli lilly and co
  • Dow pharmaceutical sciences inc
  • Paddock laboratories inc
  • Taro pharmaceuticals north america inc
  • Bioglan pharma inc
  • Alpharma us pharmaceuticals division
  • Eli lilly and co
  • Perrigo new york inc
  • Wockhardt eu operations (swiss) ag
  • Hi tech pharmacal co inc
  • Westwood squibb pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Orthoneutrogena
  • Versapharm inc
  • Ah robins co
  • Solvay pharmaceuticals
  • Watson laboratories inc
  • Life laboratories inc
  • Lilly research laboratories div eli lilly and co
  • Ross laboratories div abbott laboratories inc
  • Pharmacia and upjohn co
  • Naska pharmacal co inc div rugby darby group cosmetics
  • Wyeth ayerst laboratories
  • Abbott laboratories chemical and agricultural products div
  • Mylan pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Teva parenteral medicines inc
  • Bristol laboratories inc div bristol myers co
  • Warner chilcott div warner lambert co
  • Lederle laboratories div american cyanamid co
  • Purepac pharmaceutical co
  • Bristol myers squibb co
  • Pfizer laboratories div pfizer inc
Packagers
Dosage forms
FormRouteStrength
Tablet (enteric-coated)oral250 mg
Kit
Ointmentophthalmic5 mg
Granule, for suspensionoral200 mg/5mL
Tabletoral400 mg/1
Tablet, film coatedoral400 mg/1
Tabletoral600 mg
Powder for suspensionoral40 mg
Tabletoral200 mg
Powder for suspensionoral400 mg
Solutiontopical.8 mL/100mL
Suspensionoral200 mg/5mL
Suspensionoral400 mg/5mL
Tablet, delayed releaseoral250 mg/1
Tablet, delayed releaseoral333 mg/1
Tablet, delayed releaseoral500 mg/1
Tabletoral500 mg
Capsule (enteric-coated)oral250 mg
Capsule (enteric-coated)oral333 mg
Tabletoral250 mg
Powder for solutionintravenous1 g
Powder for solutionintravenous500 mg
Injection, powder, lyophilized, for solutionintravenous500 mg/10mL
Injection, powder, lyophilized, for solutionintravenous500 mg/100mL
Liquidoral50 mg
Liquidoral25 mg
Tabletoral500 mg/1
Tablet, film coatedoral250 mg/1
Tablet, film coatedoral500 mg/1
Capsule, delayed releaseoral250 mg/1
Capsule, delayed release pelletsoral250 mg/1
Geltopical20 mg/g
Ointmentophthalmic5 g/1
Ointmentophthalmic5 mg/g
Solutiontopical20 mg/1
Solutiontopical20 mg/mL
Geltopical
Kittopical
Granule, for suspensionoral
Capsuleoral250 mg
Ointmentophthalmic.5 mg/g
Ointmentophthalmic.5 %
Suspensionoral125 mg
Suspensionoral250 mg
Powderoral400 mg
Powder for solutionoral100 mg
Powder for solutionoral200 mg
Tabletoral333 mg
Tabletoral333 mg/1
Powder for suspensionoral
Solutiontopical
Lotiontopical
Lotion; padtopical
Prices
Unit descriptionCostUnit
Benzamycin 5-3% Gel 46.6 gm Jar236.63USD jar
BenzamycinPak 60 5-3% Packets (2 Box Contains 60 Packets)142.45USD packet
Erythromycin 2% Gel 60 gm Tube46.8USD tube
Erycette 60 2% Pad Box30.99USD box
Erythromycin 2% Gel 30 gm Tube26.2USD tube
Erythromycin 2% Solution 60ml Bottle26.13USD bottle
Eryderm 2% Solution 60ml Bottle25.99USD bottle
Erythromycin 5 mg/gm Ointment Limited Supply Available.13.99USD tube
Benzamycin gel4.95USD g
Akne-mycin 2% ointment3.96USD g
PCE 500 mg Enteric Coated Tabs3.28USD tab
Pce 500 mg dispertab3.03USD tablet
PCE 333 mg Enteric Coated Tabs2.48USD tab
Erythromycin e.s. powder2.39USD g
Benzamycinpak gel2.37USD gel
Pce 333 mg dispertab2.3USD tablet
Romycin eye ointment1.98USD g
Erythromycin eye ointment1.44USD g
Pms-Erythromycin 0.5 % Ointment1.3USD g
Emgel 2% topical gel1.07USD g
Ery-Tab 500 mg Enteric Coated Tabs0.93USD tab
Ery-tab 500 mg tablet ec0.77USD tablet
Ery-Tab 333 mg Enteric Coated Tabs0.72USD tab
Erythro-rx powder0.72USD g
Erythromycin ec 500 mg tablet0.66USD tablet
Erythromycin Base 500 mg tablet0.61USD tablet
Eryc 333 mg Capsule (Enteric-Coated Pellet)0.6USD capsule
Apo-Erythro-S 500 mg Tablet0.57USD tablet
E-mycin 333 mg tablet ec0.54USD tablet
Eryc 250 mg Capsule (Enteric-Coated Pellet)0.54USD capsule
Erythromycin powder0.54USD g
Erythromycin 2% gel0.5USD g
Erythromycin Base 250 mg Enteric Coated Capsule0.5USD capsule
Erythromycin Base 250 mg tablet0.5USD tablet
Ery-tab ec 500 mg tablet0.46USD tablet
Apo-Erythro E-C 333 mg Capsule (Enteric-Coated Pellet)0.45USD capsule
Ery-Tab 250 mg Enteric Coated Tabs0.45USD tab
Erythromycin st 500 mg tablet0.44USD tablet
Apo-Erythro E-C 250 mg Capsule (Enteric-Coated Pellet)0.41USD capsule
Ery-tab 333 mg tablet ec0.4USD tablet
Apo-Erythro-Es 600 mg Tablet0.35USD tablet
Erythromycin 500 mg filmtab0.3USD tablet
Erythrocin 500 mg filmtab0.29USD tablet
Ery-tab 250 mg tablet ec0.27USD tablet
E.e.s. 400 filmtab0.25USD tablet
Erythromycin 250 mg filmtab0.25USD tablet
Erythromycin es 400 mg tablet0.25USD tablet
Apo-Erythro-S 250 mg Tablet0.22USD tablet
Apo-Erythro Base 250 mg Tablet0.19USD tablet
Erythrocin 250 mg filmtab0.16USD tablet
Novo-Rythro Ees 80 mg/ml Suspension0.15USD ml
Novo-Rythro Estolate 50 mg/ml Suspension0.13USD ml
Novo-Rythro Ees 40 mg/ml Suspension0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191 °CPhysProp
water solubility2000mg/L at 28°CEuropean Pharmacopeia
logP3.06MCFARLAND,JW ET AL. (1997)
Caco2 permeability-5.43ADME Research, USCD
pKa8.88 (at 25 °C)MCFARLAND,JW ET AL. (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.459 mg/mLALOGPS
logP2.37ALOGPS
logP2.6ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.44ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area193.91 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity186.04 m3·mol-1ChemAxon
Polarizability78.21 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Takehiro Amano, Masami Goi, Kazuto Sekiuchi, Tomomichi Yoshida, Masahiro Hasegawa, “Process for preparing erythromycin A oxime or a salt thereof.” U.S. Patent US5274085, issued October, 1966.

US5274085
General References
  1. Kanazawa S, Ohkubo T, Sugawara K: The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):799-803. [PubMed:11294369 ]
  2. Ogwal S, Xide TU: Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci. 2001 Dec;1(2):90-6. [PubMed:12789122 ]
  3. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007 Jul;47(7):871-6. [PubMed:17585116 ]
External Links
ATC CodesD10AF52D10AF02J01FA01S01AA17
AHFS Codes
  • 08:12.12.04
  • 34:00.00
  • 52:04.04
PDB EntriesNot Available
FDA labelDownload (149 KB)
MSDSDownload (73 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Erythromycin.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Erythromycin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Erythromycin.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Erythromycin.
AcetaminophenThe serum concentration of Erythromycin can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Erythromycin.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Erythromycin.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Erythromycin.
AfatinibThe serum concentration of Erythromycin can be increased when it is combined with Afatinib.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Erythromycin.
AlbendazoleThe serum concentration of Erythromycin can be increased when it is combined with Albendazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Erythromycin.
AldosteroneThe serum concentration of Erythromycin can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Erythromycin can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Erythromycin.
AlfentanilThe serum concentration of Erythromycin can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Erythromycin.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Erythromycin.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Erythromycin.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Erythromycin.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Erythromycin.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Erythromycin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Erythromycin.
AlosetronThe metabolism of Alosetron can be decreased when combined with Erythromycin.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Erythromycin.
AmantadineAmantadine may increase the QTc-prolonging activities of Erythromycin.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Erythromycin.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Erythromycin.
Aminohippuric acidThe serum concentration of Erythromycin can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Erythromycin.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Erythromycin.
AmiodaroneErythromycin may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe serum concentration of Erythromycin can be decreased when it is combined with Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Erythromycin.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Erythromycin.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Erythromycin.
AmlodipineThe serum concentration of Erythromycin can be increased when it is combined with Amlodipine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Erythromycin.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Erythromycin.
AmprenavirThe serum concentration of Erythromycin can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Erythromycin can be increased when it is combined with Amsacrine.
AnagrelideErythromycin may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Erythromycin.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Erythromycin.
ApomorphineApomorphine may increase the QTc-prolonging activities of Erythromycin.
ApremilastThe metabolism of Apremilast can be decreased when combined with Erythromycin.
AprepitantThe serum concentration of Erythromycin can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Erythromycin.
ArformoterolArformoterol may increase the QTc-prolonging activities of Erythromycin.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Erythromycin.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Erythromycin.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Erythromycin.
Arsenic trioxideErythromycin may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherErythromycin may increase the QTc-prolonging activities of Artemether.
AsenapineErythromycin may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Erythromycin.
AstemizoleThe serum concentration of Erythromycin can be increased when it is combined with Astemizole.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Erythromycin.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Erythromycin.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Erythromycin.
AtenololThe serum concentration of Erythromycin can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Erythromycin.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Erythromycin.
AvanafilThe metabolism of Avanafil can be decreased when combined with Erythromycin.
AxitinibThe metabolism of Axitinib can be decreased when combined with Erythromycin.
AzelastineThe metabolism of Azelastine can be decreased when combined with Erythromycin.
AzelastineThe serum concentration of Erythromycin can be increased when it is combined with Azelastine.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Erythromycin.
AzithromycinThe serum concentration of Erythromycin can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Erythromycin.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Erythromycin.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Erythromycin.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Erythromycin.
BenzocaineThe serum concentration of Erythromycin can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Erythromycin.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Erythromycin.
BepridilThe serum concentration of Erythromycin can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Erythromycin.
BexaroteneThe serum concentration of Erythromycin can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Erythromycin.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Erythromycin.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Erythromycin.
BiperidenThe serum concentration of Erythromycin can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Erythromycin.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Erythromycin.
BortezomibBortezomib may increase the QTc-prolonging activities of Erythromycin.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Erythromycin.
BosentanThe serum concentration of Erythromycin can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Erythromycin.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Erythromycin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Erythromycin.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Erythromycin.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Erythromycin.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Erythromycin.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Erythromycin.
BromocriptineThe serum concentration of Erythromycin can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Erythromycin.
BudesonideThe metabolism of Budesonide can be decreased when combined with Erythromycin.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Erythromycin.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Erythromycin.
BuprenorphineThe serum concentration of Erythromycin can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Erythromycin.
BuserelinBuserelin may increase the QTc-prolonging activities of Erythromycin.
BuspironeThe metabolism of Buspirone can be decreased when combined with Erythromycin.
BuspironeThe serum concentration of Erythromycin can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Erythromycin.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Erythromycin.
CabazitaxelThe serum concentration of Erythromycin can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Erythromycin.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Erythromycin.
CaffeineThe metabolism of Caffeine can be decreased when combined with Erythromycin.
CaffeineThe serum concentration of Erythromycin can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Erythromycin.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Erythromycin.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Erythromycin.
CanagliflozinThe serum concentration of Erythromycin can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Erythromycin can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Erythromycin can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Erythromycin.
CarbamazepineThe serum concentration of Erythromycin can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Erythromycin.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Erythromycin.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Erythromycin.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Erythromycin.
CarvedilolThe serum concentration of Erythromycin can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Erythromycin can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Erythromycin.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Erythromycin.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Erythromycin.
CeritinibThe serum concentration of Erythromycin can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Erythromycin.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Erythromycin.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Erythromycin.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Erythromycin.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Erythromycin.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Erythromycin.
ChloroquineThe serum concentration of Erythromycin can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Erythromycin.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Erythromycin.
ChlorpromazineThe serum concentration of Erythromycin can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Erythromycin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Erythromycin can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Erythromycin.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Erythromycin.
CholesterolThe serum concentration of Erythromycin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Erythromycin can be decreased when it is combined with Cholic Acid.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Erythromycin.
CilazaprilThe serum concentration of Erythromycin can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Erythromycin.
CimetidineThe serum concentration of Erythromycin can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Erythromycin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Erythromycin.
CiprofloxacinThe serum concentration of Erythromycin can be increased when it is combined with Ciprofloxacin.
CisaprideErythromycin may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Erythromycin.
CitalopramErythromycin may increase the QTc-prolonging activities of Citalopram.
CitalopramThe serum concentration of Erythromycin can be increased when it is combined with Citalopram.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Erythromycin.
ClarithromycinThe serum concentration of Erythromycin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Erythromycin can be decreased when combined with Clemastine.
ClindamycinThe therapeutic efficacy of Clindamycin can be decreased when used in combination with Erythromycin.
ClobazamThe metabolism of Clobazam can be decreased when combined with Erythromycin.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Erythromycin.
ClofazimineThe serum concentration of Erythromycin can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Erythromycin.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Erythromycin.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Erythromycin.
ClomipramineClomipramine may increase the QTc-prolonging activities of Erythromycin.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Erythromycin.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Erythromycin.
ClonidineThe metabolism of Clonidine can be decreased when combined with Erythromycin.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Erythromycin.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Erythromycin.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Erythromycin.
ClotrimazoleThe metabolism of Erythromycin can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Erythromycin.
ClozapineThe metabolism of Clozapine can be decreased when combined with Erythromycin.
CobicistatThe serum concentration of Erythromycin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Erythromycin.
CocaineThe metabolism of Cocaine can be decreased when combined with Erythromycin.
CodeineThe metabolism of Codeine can be decreased when combined with Erythromycin.
ColchicineThe metabolism of Colchicine can be decreased when combined with Erythromycin.
ColchicineThe serum concentration of Erythromycin can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Erythromycin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Erythromycin can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Erythromycin.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Erythromycin.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Erythromycin.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Erythromycin.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Erythromycin.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Erythromycin.
CyclophosphamideThe serum concentration of Erythromycin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Erythromycin.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Erythromycin.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Erythromycin.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Erythromycin.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Erythromycin.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Erythromycin.
DaclatasvirThe serum concentration of Erythromycin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Erythromycin.
DactinomycinThe serum concentration of Erythromycin can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Erythromycin.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Erythromycin.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Erythromycin.
DapsoneThe metabolism of Dapsone can be decreased when combined with Erythromycin.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Erythromycin.
DarunavirThe metabolism of Darunavir can be decreased when combined with Erythromycin.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Erythromycin.
DasatinibThe serum concentration of Erythromycin can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Erythromycin.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Erythromycin.
DaunorubicinThe serum concentration of Erythromycin can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Erythromycin.
DeferasiroxThe serum concentration of Erythromycin can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Erythromycin.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Erythromycin.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Erythromycin.
DesfluraneDesflurane may increase the QTc-prolonging activities of Erythromycin.
DesipramineDesipramine may increase the QTc-prolonging activities of Erythromycin.
DesloratadineThe serum concentration of Erythromycin can be increased when it is combined with Desloratadine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Erythromycin.
DexamethasoneThe serum concentration of Erythromycin can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Erythromycin.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Erythromycin.
DextromethorphanThe serum concentration of Erythromycin can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Erythromycin.
DiazepamThe metabolism of Diazepam can be decreased when combined with Erythromycin.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Erythromycin.
DiclofenacThe serum concentration of Erythromycin can be increased when it is combined with Diclofenac.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Erythromycin.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Erythromycin.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Erythromycin.
DigoxinThe metabolism of Digoxin can be decreased when combined with Erythromycin.
DigoxinThe serum concentration of Erythromycin can be decreased when it is combined with Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Erythromycin.
DihydroergotamineThe metabolism of Erythromycin can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Erythromycin.
DiltiazemThe metabolism of Erythromycin can be decreased when combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Erythromycin.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Erythromycin.
DipyridamoleThe serum concentration of Erythromycin can be increased when it is combined with Dipyridamole.
DisopyramideErythromycin may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Erythromycin.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Erythromycin.
DofetilideErythromycin may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Erythromycin.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Erythromycin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Erythromycin.
DonepezilThe metabolism of Donepezil can be decreased when combined with Erythromycin.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Erythromycin.
DoxazosinThe serum concentration of Erythromycin can be increased when it is combined with Doxazosin.
DoxepinDoxepin may increase the QTc-prolonging activities of Erythromycin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Erythromycin.
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Erythromycin.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Erythromycin.
DoxorubicinThe serum concentration of Erythromycin can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Erythromycin can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Erythromycin.
DronedaroneErythromycin may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Erythromycin can be decreased when combined with Dronedarone.
DroperidolErythromycin may increase the QTc-prolonging activities of Droperidol.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Erythromycin.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Erythromycin.
EfavirenzThe serum concentration of Erythromycin can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Erythromycin.
ElbasvirThe serum concentration of Erythromycin can be increased when it is combined with Elbasvir.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Erythromycin.
EliglustatErythromycin may increase the QTc-prolonging activities of Eliglustat.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Erythromycin.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Erythromycin.
EnalaprilThe serum concentration of Erythromycin can be increased when it is combined with Enalapril.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Erythromycin.
EnzalutamideThe serum concentration of Erythromycin can be increased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Erythromycin.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Erythromycin.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Erythromycin.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Erythromycin.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Erythromycin.
ErgonovineThe serum concentration of Erythromycin can be increased when it is combined with Ergonovine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Erythromycin.
ErgotamineThe serum concentration of Erythromycin can be increased when it is combined with Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Erythromycin.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Erythromycin.
EscitalopramErythromycin may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Erythromycin can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Erythromycin.
EstazolamThe metabolism of Estazolam can be decreased when combined with Erythromycin.
EstradiolThe metabolism of Estradiol can be decreased when combined with Erythromycin.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Erythromycin.
EstramustineThe metabolism of Estramustine can be decreased when combined with Erythromycin.
EstramustineThe serum concentration of Erythromycin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Erythromycin.
EstroneThe metabolism of Estrone can be decreased when combined with Erythromycin.
EstroneThe serum concentration of Erythromycin can be decreased when it is combined with Estrone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Erythromycin.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Erythromycin.
EthanolThe metabolism of Ethanol can be decreased when combined with Erythromycin.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Erythromycin.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Erythromycin.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Erythromycin.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Erythromycin.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Erythromycin.
EtoposideThe metabolism of Etoposide can be decreased when combined with Erythromycin.
EtoposideThe serum concentration of Erythromycin can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Erythromycin.
EtravirineThe serum concentration of Erythromycin can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Erythromycin.
EverolimusThe metabolism of Everolimus can be decreased when combined with Erythromycin.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Erythromycin.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Erythromycin.
EzogabineEzogabine may increase the QTc-prolonging activities of Erythromycin.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Erythromycin.
FamotidineFamotidine may increase the QTc-prolonging activities of Erythromycin.
FelbamateFelbamate may increase the QTc-prolonging activities of Erythromycin.
FelbamateThe metabolism of Felbamate can be decreased when combined with Erythromycin.
FelodipineThe metabolism of Felodipine can be decreased when combined with Erythromycin.
FelodipineThe serum concentration of Erythromycin can be increased when it is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Erythromycin.
FentanylThe metabolism of Fentanyl can be decreased when combined with Erythromycin.
FentanylThe serum concentration of Erythromycin can be increased when it is combined with Fentanyl.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Erythromycin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Erythromycin.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Erythromycin.
FidaxomicinThe serum concentration of Erythromycin can be increased when it is combined with Fidaxomicin.
FinasterideThe metabolism of Finasteride can be decreased when combined with Erythromycin.
FingolimodFingolimod may increase the QTc-prolonging activities of Erythromycin.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Erythromycin.
FlecainideErythromycin may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Erythromycin.
FluconazoleFluconazole may increase the QTc-prolonging activities of Erythromycin.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Erythromycin.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Erythromycin.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Erythromycin.
FluoxetineErythromycin may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe serum concentration of Erythromycin can be increased when it is combined with Fluoxetine.
FlupentixolErythromycin may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe serum concentration of Erythromycin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Erythromycin can be increased when it is combined with Fluphenazine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Erythromycin.
FlurazepamThe serum concentration of Erythromycin can be increased when it is combined with Flurazepam.
FlutamideThe metabolism of Flutamide can be decreased when combined with Erythromycin.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Erythromycin.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Erythromycin.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Erythromycin.
FluvoxamineThe metabolism of Erythromycin can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Erythromycin.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Erythromycin.
FosaprepitantThe serum concentration of Erythromycin can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Erythromycin.
FosphenytoinThe metabolism of Erythromycin can be increased when combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Erythromycin.
Fusidic AcidThe serum concentration of Erythromycin can be increased when it is combined with Fusidic Acid.
Gadobenic acidErythromycin may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Erythromycin.
GalantamineThe metabolism of Galantamine can be decreased when combined with Erythromycin.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Erythromycin.
GefitinibThe serum concentration of Erythromycin can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Erythromycin.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Erythromycin.
GemifloxacinErythromycin may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Erythromycin can be increased when it is combined with Genistein.
GlipizideThe metabolism of Glipizide can be decreased when combined with Erythromycin.
GlyburideThe metabolism of Glyburide can be decreased when combined with Erythromycin.
GlyburideThe serum concentration of Erythromycin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Erythromycin can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Erythromycin.
Gramicidin DThe serum concentration of Erythromycin can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Erythromycin.
GranisetronThe metabolism of Granisetron can be decreased when combined with Erythromycin.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Erythromycin.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Erythromycin.
GrepafloxacinThe serum concentration of Erythromycin can be increased when it is combined with Grepafloxacin.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Erythromycin.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Erythromycin.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Erythromycin.
HaloperidolThe serum concentration of Erythromycin can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Erythromycin.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Erythromycin.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Erythromycin.
HistrelinHistrelin may increase the QTc-prolonging activities of Erythromycin.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Erythromycin.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Erythromycin.
HydrocortisoneThe serum concentration of Erythromycin can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Erythromycin.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Erythromycin.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Erythromycin.
IbandronateIbandronate may increase the QTc-prolonging activities of Erythromycin.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Erythromycin.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Erythromycin.
IbutilideErythromycin may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Erythromycin can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Erythromycin.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Erythromycin resulting in a loss in efficacy.
IloperidoneErythromycin may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Erythromycin.
ImatinibThe metabolism of Erythromycin can be decreased when combined with Imatinib.
ImipramineImipramine may increase the QTc-prolonging activities of Erythromycin.
ImipramineThe metabolism of Imipramine can be decreased when combined with Erythromycin.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Erythromycin.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Erythromycin.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Erythromycin.
IndapamideIndapamide may increase the QTc-prolonging activities of Erythromycin.
IndapamideThe metabolism of Indapamide can be decreased when combined with Erythromycin.
IndinavirThe metabolism of Indinavir can be decreased when combined with Erythromycin.
IndinavirThe serum concentration of Erythromycin can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Erythromycin.
IndomethacinThe serum concentration of Erythromycin can be increased when it is combined with Indomethacin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Erythromycin.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Erythromycin.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Erythromycin.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Erythromycin.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Erythromycin.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Erythromycin.
IsradipineIsradipine may increase the QTc-prolonging activities of Erythromycin.
IsradipineThe metabolism of Isradipine can be decreased when combined with Erythromycin.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Erythromycin.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Erythromycin.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Erythromycin.
IvabradineIvabradine may increase the QTc-prolonging activities of Erythromycin.
IvacaftorThe serum concentration of Erythromycin can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Erythromycin.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Erythromycin.
IvermectinThe serum concentration of Erythromycin can be increased when it is combined with Ivermectin.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Erythromycin.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Erythromycin.
KetamineThe metabolism of Ketamine can be decreased when combined with Erythromycin.
KetamineThe serum concentration of Erythromycin can be increased when it is combined with Ketamine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Erythromycin.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Erythromycin.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Erythromycin.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Erythromycin.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Erythromycin.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Erythromycin.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Erythromycin.
LansoprazoleThe serum concentration of Erythromycin can be increased when it is combined with Lansoprazole.
LapatinibLapatinib may increase the QTc-prolonging activities of Erythromycin.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Erythromycin.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Erythromycin.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Erythromycin.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Erythromycin.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Erythromycin.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Erythromycin.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Erythromycin.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Erythromycin.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Erythromycin.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Erythromycin.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Erythromycin.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Erythromycin.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Erythromycin.
LevofloxacinThe serum concentration of Erythromycin can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Erythromycin.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Erythromycin.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Erythromycin.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Erythromycin.
LevothyroxineThe serum concentration of Erythromycin can be decreased when it is combined with Levothyroxine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Erythromycin.
LidocaineThe serum concentration of Erythromycin can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Erythromycin.
LiothyronineThe serum concentration of Erythromycin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Erythromycin can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Erythromycin can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Erythromycin.
LithiumLithium may increase the QTc-prolonging activities of Erythromycin.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Erythromycin.
LoperamideThe metabolism of Loperamide can be decreased when combined with Erythromycin.
LoperamideThe serum concentration of Erythromycin can be increased when it is combined with Loperamide.
LopinavirErythromycin may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe serum concentration of Erythromycin can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Erythromycin.
LoratadineThe serum concentration of Erythromycin can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Erythromycin.
LosartanThe metabolism of Losartan can be decreased when combined with Erythromycin.
LosartanThe serum concentration of Erythromycin can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Erythromycin.
LovastatinThe metabolism of Erythromycin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Erythromycin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Erythromycin can be decreased when it is combined with Lumacaftor.
LumefantrineErythromycin may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Erythromycin.
MacitentanThe metabolism of Macitentan can be decreased when combined with Erythromycin.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Erythromycin.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Erythromycin.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Erythromycin.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Erythromycin.
MebendazoleThe serum concentration of Erythromycin can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Erythromycin.
MefloquineMefloquine may increase the QTc-prolonging activities of Erythromycin.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Erythromycin.
Megestrol acetateThe serum concentration of Erythromycin can be increased when it is combined with Megestrol acetate.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Erythromycin.
MeprobamateThe serum concentration of Erythromycin can be increased when it is combined with Meprobamate.
MequitazineErythromycin may increase the arrhythmogenic activities of Mequitazine.
MethadoneThe metabolism of Methadone can be decreased when combined with Erythromycin.
MethadoneThe serum concentration of Erythromycin can be increased when it is combined with Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Erythromycin.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Erythromycin.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Erythromycin.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Erythromycin.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Erythromycin.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Erythromycin.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Erythromycin.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Erythromycin.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Erythromycin.
MetoprololThe serum concentration of Erythromycin can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Erythromycin.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Erythromycin.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Erythromycin.
MianserinThe metabolism of Mianserin can be decreased when combined with Erythromycin.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Erythromycin.
MibefradilThe serum concentration of Erythromycin can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Erythromycin.
MiconazoleThe serum concentration of Erythromycin can be increased when it is combined with Miconazole.
MidazolamThe metabolism of Midazolam can be decreased when combined with Erythromycin.
MidazolamThe serum concentration of Erythromycin can be decreased when it is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Erythromycin.
MirabegronMirabegron may increase the QTc-prolonging activities of Erythromycin.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Erythromycin.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Erythromycin.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Erythromycin.
MitomycinThe serum concentration of Erythromycin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Erythromycin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Erythromycin.
ModafinilThe serum concentration of Erythromycin can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Erythromycin.
MoexiprilMoexipril may increase the QTc-prolonging activities of Erythromycin.
MontelukastThe metabolism of Montelukast can be decreased when combined with Erythromycin.
MorphineThe metabolism of Morphine can be decreased when combined with Erythromycin.
MorphineThe serum concentration of Erythromycin can be increased when it is combined with Morphine.
MoxifloxacinErythromycin may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Erythromycin.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Erythromycin.
NafcillinThe serum concentration of Erythromycin can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Erythromycin.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Erythromycin.
NaltrexoneThe serum concentration of Erythromycin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Erythromycin can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Erythromycin.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Erythromycin.
NefazodoneThe serum concentration of Erythromycin can be decreased when it is combined with Nefazodone.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Erythromycin.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Erythromycin.
NeostigmineThe serum concentration of Erythromycin can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Erythromycin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Erythromycin can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Erythromycin.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Erythromycin.
NicotineThe metabolism of Nicotine can be decreased when combined with Erythromycin.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Erythromycin.
NifedipineThe serum concentration of Erythromycin can be decreased when it is combined with Nifedipine.
NilotinibErythromycin may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Erythromycin can be decreased when combined with Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Erythromycin.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Erythromycin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Erythromycin.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Erythromycin.
NisoldipineThe serum concentration of Erythromycin can be increased when it is combined with Nisoldipine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Erythromycin.
NitrazepamThe serum concentration of Erythromycin can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Erythromycin.
NitrendipineThe serum concentration of Erythromycin can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Erythromycin.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Erythromycin.
NorethisteroneThe serum concentration of Erythromycin can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Erythromycin.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Erythromycin.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Erythromycin.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Erythromycin.
OctreotideOctreotide may increase the QTc-prolonging activities of Erythromycin.
OfloxacinErythromycin may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Erythromycin.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Erythromycin.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Erythromycin.
OlaparibThe metabolism of Erythromycin can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Erythromycin.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Erythromycin.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Erythromycin.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Erythromycin.
OmeprazoleThe serum concentration of Erythromycin can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Erythromycin.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Erythromycin.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Erythromycin.
OsimertinibThe serum concentration of Erythromycin can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Erythromycin.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Erythromycin.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Erythromycin.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Erythromycin.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Erythromycin.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Erythromycin.
OxytocinOxytocin may increase the QTc-prolonging activities of Erythromycin.
P-NitrophenolThe serum concentration of Erythromycin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Erythromycin.
PaclitaxelThe serum concentration of Erythromycin can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Erythromycin can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Erythromycin.
PaliperidoneErythromycin may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Erythromycin can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Erythromycin.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Erythromycin.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Erythromycin.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Erythromycin.
PantoprazoleThe serum concentration of Erythromycin can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Erythromycin.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Erythromycin.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Erythromycin.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Erythromycin.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Erythromycin.
ParoxetineParoxetine may increase the QTc-prolonging activities of Erythromycin.
PasireotidePasireotide may increase the QTc-prolonging activities of Erythromycin.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Erythromycin.
PazopanibPazopanib may increase the QTc-prolonging activities of Erythromycin.
PentamidinePentamidine may increase the QTc-prolonging activities of Erythromycin.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Erythromycin.
PentobarbitalThe metabolism of Erythromycin can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Erythromycin.
PerflutrenErythromycin may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Erythromycin.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Erythromycin.
PerindoprilThe serum concentration of Erythromycin can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Erythromycin.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Erythromycin.
PethidineThe metabolism of Pethidine can be decreased when combined with Erythromycin.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Erythromycin.
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Erythromycin.
PhenobarbitalThe serum concentration of Erythromycin can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Erythromycin.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Erythromycin.
PhenytoinThe metabolism of Erythromycin can be increased when combined with Phenytoin.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Erythromycin.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Erythromycin.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Erythromycin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Erythromycin.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Erythromycin.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Erythromycin.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Erythromycin.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Erythromycin.
Platelet Activating FactorThe serum concentration of Erythromycin can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Erythromycin.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Erythromycin.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Erythromycin.
PonatinibThe serum concentration of Erythromycin can be increased when it is combined with Ponatinib.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Erythromycin.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Erythromycin.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Erythromycin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Erythromycin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Erythromycin.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Erythromycin.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Erythromycin.
PrazosinThe serum concentration of Erythromycin can be increased when it is combined with Prazosin.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Erythromycin.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Erythromycin.
PrednisoneThe serum concentration of Erythromycin can be increased when it is combined with Prednisone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Erythromycin.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Erythromycin.
PrimidoneThe metabolism of Erythromycin can be increased when combined with Primidone.
ProbenecidThe serum concentration of Erythromycin can be increased when it is combined with Probenecid.
ProcainamideErythromycin may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Erythromycin.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Erythromycin.
ProgesteroneThe serum concentration of Erythromycin can be decreased when it is combined with Progesterone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Erythromycin.
PromazinePromazine may increase the QTc-prolonging activities of Erythromycin.
PromazineThe metabolism of Promazine can be decreased when combined with Erythromycin.
PromethazinePromethazine may increase the QTc-prolonging activities of Erythromycin.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Erythromycin.
PropofolPropofol may increase the QTc-prolonging activities of Erythromycin.
PropofolThe metabolism of Propofol can be decreased when combined with Erythromycin.
PropranololThe metabolism of Propranolol can be decreased when combined with Erythromycin.
PropranololThe serum concentration of Erythromycin can be increased when it is combined with Propranolol.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Erythromycin.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Erythromycin.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Erythromycin.
QuazepamThe serum concentration of Erythromycin can be increased when it is combined with Quazepam.
QuazepamThe metabolism of Quazepam can be decreased when combined with Erythromycin.
QuercetinThe serum concentration of Erythromycin can be increased when it is combined with Quercetin.
QuetiapineErythromycin may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Erythromycin.
QuinacrineThe serum concentration of Erythromycin can be increased when it is combined with Quinacrine.
QuinidineErythromycin may increase the QTc-prolonging activities of Quinidine.
QuinidineThe serum concentration of Erythromycin can be increased when it is combined with Quinidine.
QuinineErythromycin may increase the QTc-prolonging activities of Quinine.
QuinineThe serum concentration of Erythromycin can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Erythromycin.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Erythromycin.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Erythromycin.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Erythromycin.
RanitidineThe serum concentration of Erythromycin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Erythromycin can be increased when it is combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Erythromycin.
ReboxetineThe serum concentration of Erythromycin can be increased when it is combined with Reboxetine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Erythromycin.
RegorafenibThe serum concentration of Erythromycin can be increased when it is combined with Regorafenib.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Erythromycin.
ReserpineThe serum concentration of Erythromycin can be decreased when it is combined with Reserpine.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Erythromycin.
RifabutinThe metabolism of Erythromycin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Erythromycin.
RifampicinThe serum concentration of Erythromycin can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Erythromycin can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Erythromycin.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Erythromycin.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Erythromycin.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Erythromycin.
RiociguatThe metabolism of Riociguat can be decreased when combined with Erythromycin.
RisperidoneRisperidone may increase the QTc-prolonging activities of Erythromycin.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Erythromycin.
RitonavirRitonavir may increase the QTc-prolonging activities of Erythromycin.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Erythromycin.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Erythromycin.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Erythromycin.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Erythromycin.
RolapitantThe serum concentration of Erythromycin can be increased when it is combined with Rolapitant.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Erythromycin.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Erythromycin.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Erythromycin.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Erythromycin.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Erythromycin.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Erythromycin.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Erythromycin.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Erythromycin.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Erythromycin.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Erythromycin.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Erythromycin.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Erythromycin.
SaquinavirThe serum concentration of Erythromycin can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Erythromycin.
ScopolamineThe serum concentration of Erythromycin can be increased when it is combined with Scopolamine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Erythromycin.
SelegilineThe serum concentration of Erythromycin can be increased when it is combined with Selegiline.
SelexipagThe metabolism of Selexipag can be decreased when combined with Erythromycin.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Erythromycin.
SertindoleThe metabolism of Sertindole can be decreased when combined with Erythromycin.
SertralineSertraline may increase the QTc-prolonging activities of Erythromycin.
SertralineThe metabolism of Sertraline can be decreased when combined with Erythromycin.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Erythromycin.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Erythromycin.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Erythromycin.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Erythromycin.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Erythromycin.
SiltuximabThe serum concentration of Erythromycin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Erythromycin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Erythromycin.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Erythromycin.
SirolimusThe serum concentration of Erythromycin can be decreased when it is combined with Sirolimus.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Erythromycin.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Erythromycin.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Erythromycin.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Erythromycin.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Erythromycin.
SorafenibSorafenib may increase the QTc-prolonging activities of Erythromycin.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Erythromycin.
SotalolErythromycin may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Erythromycin.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Erythromycin.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Erythromycin.
SpironolactoneThe serum concentration of Erythromycin can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Erythromycin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Erythromycin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Erythromycin can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Erythromycin can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Erythromycin.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Erythromycin.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Erythromycin.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Erythromycin.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Erythromycin.
SulfinpyrazoneThe serum concentration of Erythromycin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleErythromycin may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Erythromycin can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Erythromycin can be increased when it is combined with Sumatriptan.
SunitinibSunitinib may increase the QTc-prolonging activities of Erythromycin.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Erythromycin.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Erythromycin.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Erythromycin.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Erythromycin.
TacrineThe serum concentration of Erythromycin can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Erythromycin.
TacrolimusThe serum concentration of Erythromycin can be decreased when it is combined with Tacrolimus.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Erythromycin.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Erythromycin.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Erythromycin.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Erythromycin.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Erythromycin.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Erythromycin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Erythromycin.
Taurocholic AcidThe serum concentration of Erythromycin can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Erythromycin.
TelaprevirThe serum concentration of Erythromycin can be increased when it is combined with Telaprevir.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Erythromycin.
TelavancinErythromycin may increase the QTc-prolonging activities of Telavancin.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Erythromycin.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Erythromycin.
TelmisartanThe serum concentration of Erythromycin can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Erythromycin.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Erythromycin.
TemsirolimusThe serum concentration of Erythromycin can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be decreased when combined with Erythromycin.
TerazosinThe serum concentration of Erythromycin can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Erythromycin.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Erythromycin.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Erythromycin.
TerfenadineThe serum concentration of Erythromycin can be increased when it is combined with Terfenadine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Erythromycin.
TesmilifeneThe serum concentration of Erythromycin can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Erythromycin.
TestosteroneThe serum concentration of Erythromycin can be increased when it is combined with Testosterone.
TetrabenazineErythromycin may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Erythromycin.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Erythromycin.
ThioridazineErythromycin may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Erythromycin.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Erythromycin.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Erythromycin.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Erythromycin.
TicagrelorThe serum concentration of Erythromycin can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Erythromycin can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Erythromycin.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Erythromycin.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Erythromycin.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Erythromycin.
TizanidineTizanidine may increase the QTc-prolonging activities of Erythromycin.
TocilizumabThe serum concentration of Erythromycin can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Erythromycin.
TolterodineTolterodine may increase the QTc-prolonging activities of Erythromycin.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Erythromycin.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Erythromycin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Erythromycin.
ToremifeneErythromycin may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Erythromycin.
TramadolThe metabolism of Tramadol can be decreased when combined with Erythromycin.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Erythromycin.
TrazodoneTrazodone may increase the QTc-prolonging activities of Erythromycin.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Erythromycin.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Erythromycin.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Erythromycin.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Erythromycin.
TriazolamThe metabolism of Triazolam can be decreased when combined with Erythromycin.
TrifluoperazineThe serum concentration of Erythromycin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Erythromycin can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Erythromycin.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Erythromycin.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Erythromycin.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Erythromycin.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Erythromycin.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Erythromycin.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Erythromycin.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Erythromycin.
TroleandomycinThe serum concentration of Erythromycin can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be decreased when combined with Erythromycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Erythromycin.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Erythromycin.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Erythromycin.
VandetanibErythromycin may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Erythromycin.
VardenafilVardenafil may increase the QTc-prolonging activities of Erythromycin.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Erythromycin.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Erythromycin.
VemurafenibErythromycin may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Erythromycin.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Erythromycin.
VerapamilThe metabolism of Verapamil can be decreased when combined with Erythromycin.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Erythromycin.
VilanterolVilanterol may increase the QTc-prolonging activities of Erythromycin.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Erythromycin.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Erythromycin.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Erythromycin.
VinblastineThe serum concentration of Erythromycin can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Erythromycin.
VincristineThe serum concentration of Erythromycin can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Erythromycin.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Erythromycin.
VinorelbineThe serum concentration of Erythromycin can be increased when it is combined with Vinorelbine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Erythromycin.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Erythromycin.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Erythromycin.
VorinostatVorinostat may increase the QTc-prolonging activities of Erythromycin.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Erythromycin.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Erythromycin.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Erythromycin.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Erythromycin.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Erythromycin.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Erythromycin.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Erythromycin.
ZileutonThe metabolism of Zileuton can be decreased when combined with Erythromycin.
ZimelidineThe serum concentration of Erythromycin can be increased when it is combined with Zimelidine.
ZiprasidoneErythromycin may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Erythromycin can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Erythromycin.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Erythromycin.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Erythromycin.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Erythromycin.
ZuclopenthixolErythromycin may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water Avoid taking with grapefruit juice.

Targets

1. 23S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
yes
Actions
inhibitor
References
  1. Moazed D, Noller HF: Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie. 1987 Aug;69(8):879-84. [PubMed:3122849 ]
  2. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. [PubMed:11677599 ]
  3. Garza-Ramos G, Xiong L, Zhong P, Mankin A: Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol. 2001 Dec;183(23):6898-907. [PubMed:11698379 ]
Kind
Protein
Organism
Escherichia coli O157:H7
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of ribosome
Specific Function:
This protein binds specifically to 23S rRNA; its binding is stimulated by other ribosomal proteins, e.g. L4, L17, and L20. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome (By similarity).The globular domain of the protein is located near the polypeptide exit tunnel on the outside...
Gene Name:
rplV
Uniprot ID:
P61177
Molecular Weight:
12226.165 Da
References
  1. Halling SM, Jensen AE: Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications. BMC Microbiol. 2006 Oct 2;6:84. [PubMed:17014718 ]
  2. Tu D, Blaha G, Moore PB, Steitz TA: Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005 Apr 22;121(2):257-70. [PubMed:15851032 ]
  3. Rolain JM, Raoult D: Prediction of resistance to erythromycin in the genus Rickettsia by mutations in L22 ribosomal protein. J Antimicrob Chemother. 2005 Aug;56(2):396-8. Epub 2005 Jul 4. [PubMed:15996971 ]
  4. Cagliero C, Mouline C, Cloeckaert A, Payot S: Synergy between efflux pump CmeABC and modifications in ribosomal proteins L4 and L22 in conferring macrolide resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 2006 Nov;50(11):3893-6. Epub 2006 Aug 28. [PubMed:16940070 ]
  5. Schlunzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure. 2003 Mar;11(3):329-38. [PubMed:12623020 ]
  6. Davydova N, Streltsov V, Wilce M, Liljas A, Garber M: L22 ribosomal protein and effect of its mutation on ribosome resistance to erythromycin. J Mol Biol. 2002 Sep 20;322(3):635-44. [PubMed:12225755 ]
Kind
Protein
Organism
Escherichia coli O157:H7
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of ribosome
Specific Function:
One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome.Protein L4 is a both a transcriptional repressor and a translational repressor protein. It regulates transcription of the S10 op...
Gene Name:
rplD
Uniprot ID:
P60725
Molecular Weight:
22086.36 Da
References
  1. Halling SM, Jensen AE: Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications. BMC Microbiol. 2006 Oct 2;6:84. [PubMed:17014718 ]
  2. Tu D, Blaha G, Moore PB, Steitz TA: Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005 Apr 22;121(2):257-70. [PubMed:15851032 ]
  3. O'Connor M, Gregory ST, Dahlberg AE: Multiple defects in translation associated with altered ribosomal protein L4. Nucleic Acids Res. 2004 Oct 27;32(19):5750-6. Print 2004. [PubMed:15509870 ]
  4. Schlunzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure. 2003 Mar;11(3):329-38. [PubMed:12623020 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Growth hormone-releasing hormone receptor activity
Specific Function:
Receptor for motilin.
Gene Name:
MLNR
Uniprot ID:
O43193
Molecular Weight:
45343.725 Da
References
  1. Li JJ, Chao HG, Wang H, Tino JA, Lawrence RM, Ewing WR, Ma Z, Yan M, Slusarchyk D, Seethala R, Sun H, Li D, Burford NT, Stoffel RH, Salyan ME, Li CY, Witkus M, Zhao N, Rich A, Gordon DA: Discovery of a potent and novel motilin agonist. J Med Chem. 2004 Mar 25;47(7):1704-8. [PubMed:15027861 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Du LP, Tsai KC, Li MY, You QD, Xia L: The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4771-7. [PubMed:15324906 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sterol 14-demethylase activity
Specific Function:
Catalyzes C14-demethylation of lanosterol; it transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name:
CYP51A1
Uniprot ID:
Q16850
Molecular Weight:
56805.26 Da
References
  1. Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ Jr: Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500. Epub 2006 Dec 28. [PubMed:17194716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Monovalent cation:proton antiporter activity
Specific Function:
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport...
Gene Name:
SLC47A1
Uniprot ID:
Q96FL8
Molecular Weight:
61921.585 Da
References
  1. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM: Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013 Feb 14;56(3):781-95. doi: 10.1021/jm301302s. Epub 2013 Jan 22. [PubMed:23241029 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  3. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  4. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  5. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol. 1998 Oct 9;358(3):289-94. [PubMed:9822896 ]
  6. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
  7. Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9. [PubMed:14744620 ]
  8. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  9. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  10. Sun H, Huang Y, Frassetto L, Benet LZ: Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004 Nov;32(11):1239-46. Epub 2004 Jul 30. [PubMed:15286055 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, Suenaga M, Tei C, Kohno S: Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother. 2000 Jun;44(6):1697-700. [PubMed:10817732 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T: Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. Epub 2005 Feb 11. [PubMed:15708966 ]
  2. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23